Are you Dr. Doi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 44 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3601 5th Ave
# Falk
Pittsburgh, PA 15213Phone+1 412-648-6401Fax+1 412-648-6399
Summary
- Dr. Yohei Doi, MD is an infectious disease specialist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania. He is affiliated with UPMC Presbyterian Shadyside and UPMC Magee-Womens Hospital.
Education & Training
- UPMC Medical EducationFellowship, Infectious Disease, 2005 - 2008
- Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2003 - 2005
- Nagoya University - School of MedicineClass of 1998
Certifications & Licensure
- PA State Medical License 2005 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Gram Negative Bacteremia, Risk Factors for Failure of Therapy Start of enrollment: 2005 Apr 01
- Mechanisms of Resistance and Molecular Epidemiology of Commonly Encountered Multi-Resistant Bacteria Start of enrollment: 2006 Jan 01
- Community - Associated Extended-spectrum Beta-lactamases (ESBL) Start of enrollment: 2006 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 148 citationsTreatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii InfectionsJ. Alexander Viehman, M. Hong Nguyen, Yohei Doi
Drugs. 2014-08-05 - 85 citationsClinical Outcomes of Hospital-Acquired Infection with Acinetobacter nosocomialis and Acinetobacter pittiiSarunyou Chusri, Virasakdi Chongsuvivatwong, Jesabel I. Rivera, Kachornsakdi Silpapojakul, Kamonnut Singkhamanan
Antimicrobial Agents and Chemotherapy. 2014-07-01 - 22 citationsReduced Susceptibility to Cefepime among Escherichia coli Clinical Isolates Producing Novel Variants of CMY-2 β-LactamaseYohei Doi, David L. Paterson, Jennifer M. Adams-Haduch, Hanna E. Sidjabat, Alexandra O'Keefe
Antimicrobial Agents and Chemotherapy. 2009-07-01
Press Mentions
- Fujita Health University Favipiravir Trial Evidences No Statistically Conclusive Benefit to COVID-19 Patients: A Question Mark for Favipiravir?July 11th, 2020
- WHO Studies File International Each Day Coronavirus Circumstances Improve: LiveJuly 10th, 2020
- No Pause in Coronavirus Trial for Avigan, Japan's Lead Researcher SaysMay 20th, 2020
- Join now to see all
Grant Support
- Multidrug-Resistant Acinetobacter BaumanniiNational Institute Of Allergy And Infectious Diseases2009–2010
- Epidemiology Of Community-Associated, Esbl-Producing Escherichia ColiNational Institute Of Allergy And Infectious Diseases2009–2010
Professional Memberships
- Member